Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07143955 | Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC) | completed | N/A | 100 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04871321 | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer | completed | — | 119 | CHA UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT04191421 |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer |
| completed |
| Phase 1 / Phase 2 |
| 35 |
| Emory UniversityOTHER |
| 1 |
| Aug 22, 2025 |
| clinicaltrials |
| NCT03638141 | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | completed | Phase 2 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03579771 | Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06620510 | Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea | completed | — | 230 | GC Cell CorporationINDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT04791176 | Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | completed | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04825834 | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)(DELFI-L101) | completed | — | 2,992 | Delfi Diagnostics Inc.INDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05678218 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma(POELH-II) | completed | — | 245 | Erasmus Medical CenterOTHER | 2 | Aug 8, 2025 | clinicaltrials |
| NCT04634539 | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | completed | Phase 1 | 18 | Jun Gong, MDOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT02375880 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | completed | Phase 1 | 51 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06048367 | Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor(CNSI-Fe(II)) | completed | Phase 1 | 19 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05616039 | I-FIGS Feasibility Study(I-FIGS) | completed | N/A | 42 | University Hospital Plymouth NHS TrustOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03033225 | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT01356628 | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | completed | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06156748 | CT Imaging for Guiding PA-TACE for HCC | completed | — | 1,770 | Zhujiang HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT02030860 | A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | completed | Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03377179 | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma | completed | Phase 2 | 65 | RedHill Biopharma LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04069468 | Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)(PROACTIF) | completed | — | 1,247 | Boston Scientific CorporationINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05101629 | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | completed | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07075562 | TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion | completed | N/A | 180 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04923529 | TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma | completed | Phase 2 | 28 | The University of Hong KongOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05078775 | Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer | completed | N/A | 39 | Faeth TherapeuticsINDUSTRY | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02312817 | RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System | completed | N/A | 1,800 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02940496 | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT07053202 | TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma | completed | N/A | 140 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06481397 | OSCAR I STUDY - The ONCObind CTC Removal Study | completed | N/A | 5 | ExThera Medical CorporationINDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02723331 | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | completed | Phase 2 | 48 | Academic Thoracic Oncology Medical Investigators ConsortiumINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | completed | Phase 1 | 19 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03592888 | DC Vaccine in Pancreatic Cancer | completed | Phase 1 | 29 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07030842 | Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma | completed | — | 579 | Tongji HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT02078700 | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. | completed | Phase 2 | 40 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05635279 | Effect of Nutritional Indices on the Prognosis of HCC Patients | completed | — | 150 | Juan KangOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07034495 | Laparotomy, Laparoscopy, da Vinci System | completed | — | 486 | National Chung Hsing UniversityOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03267524 | Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers | completed | N/A | 87 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT04422730 | Evolution of Body Connection After Surgery | completed | — | 129 | Institut Paoli-CalmettesOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03572283 | Bethanechol Prior to Pancreatic Surgery | completed | Early Phase 1 | 17 | Columbia UniversityOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05440942 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 28 | Peter Hosein, MDOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03250273 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | completed | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2025source: clinicaltrials